Abstract
In the Republic of Kazakhstan, over the past two decades, professionals in the field of healthcare and the circulation of medicines and medical products have paid the greatest attention to assessing the economic feasibility of using certain medical technologies and medicines. The emergence of new medical technologies and modern effective, often expensive medicines, on the one hand, and a slight increase in the economic resources of healthcare, on the other, raises the issue of providing patients with high-quality and sufficient medical care. Pharmacoeconomic analysis, in particular the analysis of the «cost of illness», is one of the tools that facilitate decision-making in the financing of various nosologies in the healthcare system. The article publishes the results of a pharmacoeconomical study using the method «cost of illness» for antihypertensive therapy. In the course of the study, an analysis of the costs of antihypertensive therapy in outpatient and inpatient settings was carried out.